IVF Automation Technology: The Proven Innovations Behind AURA

When AURA identifies an oocyte within follicular fluid, it's using the same real-time object-detection architecture that helps autonomous vehicles navigate traffic at 70 miles per hour.

That architecture is YOLO—You Only Look Once—a foundational algorithm in computer vision that processes an entire image in a single forward pass through a neural network. Traditional computer-vision systems identify areas of interest first, then classify them in separate steps.

YOLO collapses that pipeline into one instantaneous decision.

That design made YOLO—and the generation of single-shot detectors that followed—essential to latency-critical perception systems. Companies like Tesla, Waymo, and Baidu deploy these architectures because they work in the real world, under real constraints, where identifying objects accurately in milliseconds isn't optional.

We adapted that proven approach for a different challenge: locating oocytes within cumulus-oocyte complexes during retrieval.

AURA combines YOLO with RT-DETR (Real-Time Detection Transformer)—a state-of-the-art, end-to-end object detector—to create machine vision for egg discovery. The system identifies oocytes surrounded by cumulus cells, determines their position with sub-micron precision, and flags them for retrieval in real time. It does this under the environmental constraints of an active IVF lab: 37°C, 5% CO₂, and high humidity.

The algorithm doesn't just find eggs—it finds them faster and more consistently than manual inspection. That matters when you're processing multiple retrievals simultaneously and every oocyte counts.

The Adjacent Possible in Action

This is what we call The In Vitro Possible—a concept rooted in theoretical biologist Stuart Kauffman's idea of "The Adjacent Possible." Kauffman, a MacArthur Genius, describes it this way: "What is actual now enables what is next possible."

Historian Steven Johnson offers a more accessible translation: "At any moment, the world is capable of extraordinary change. But only certain changes."

Great innovations rarely emerge from inventing everything from scratch. They emerge by recognizing when disparate technologies can be recombined to unlock what was previously impossible. Steve Jobs didn't invent the cell phone, touchscreen, or GPS—but he had the vision to synthesize them into the iPhone, democratizing computing for 85% of the global population. AURA follows the same principle. We didn't invent machine vision, precision robotics, or advanced microscopy. We borrowed the best tools that already exist—technologies proven in automotive safety, ophthalmology, and semiconductor manufacturing—and applied them to solve one of healthcare's most pressing scalability challenges.

Seeing What Matters: Optical Coherence Tomography

AURA's imaging capabilities rely on optical coherence tomography (OCT)—a non-invasive technique originally developed for retinal imaging that creates high-resolution, three-dimensional cross-sections of biological tissue.

In ophthalmology, OCT allows clinicians to visualize microscopic structures within the eye without physical contact. In AURA, that same technology enables precise visualization of oocytes, embryos, and cellular structures during critical procedures like ICSI (intracytoplasmic sperm injection) and embryo biopsy.

Traditional brightfield microscopy captures a two-dimensional image. OCT adds depth—literally. That additional dimension improves accuracy during micromanipulation and reduces the risk of damage to delicate cells. When you're working with structures measured in microns, that precision isn't a luxury. It's fundamental.

Precision at Scale: Robotics from Semiconductor Manufacturing

The micro-pipettes AURA uses to manipulate oocytes and embryos move with tolerances adapted from semiconductor manufacturing—an industry where precision is measured in nanometers and errors cost millions.

Automated pick-and-place systems used in chip assembly require sub-micron accuracy to position components smaller than a grain of salt. That same level of control now guides AURA's pipettes during denudation, ICSI, and biopsy procedures.

The result: reproducible, standardized movements that reduce variability across procedures and labs. Human embryologists bring irreplaceable expertise to decision-making and oversight. AURA amplifies that expertise by eliminating the physical fatigue and variability inherent in performing hundreds of manual procedures daily.

Navigation Systems: From Roads to Petri Dishes

Autonomous vehicle technology doesn't just inform AURA's object detection—it shapes how the system navigates complex environments in real time.

Baidu's Apollo autonomous driving platform, for example, uses sensor fusion and real-time decision-making to interpret dynamic environments: pedestrians, cyclists, traffic signals, weather conditions. The system doesn't just detect objects—it predicts movement, prioritizes actions, and adjusts continuously.

AURA applies similar principles within the IVF lab. During oocyte retrieval, the system processes multiple data streams simultaneously: visual input from microscopy, positional data from robotics, environmental monitoring from lab sensors. It identifies oocytes, tracks their location as fluid moves, and coordinates retrieval—all while maintaining the precise temperature, humidity, and CO₂ levels embryos require.

The parallels aren't coincidental. Both systems operate in environments where milliseconds matter, conditions change unpredictably, and failure isn't acceptable.

Why This Matters Now

Walk into most IVF laboratories today and you'll see a process that hasn't fundamentally changed since the 1990s. Embryologists work manually with microscopes and pipettes, performing hundreds of delicate procedures by hand. It's extraordinary in its ability to create life—and extremely difficult to scale.

Scale is exactly what's needed. According to a 2023 paper in Fertility and Sterility, true global demand sits around 20 million IVF births annually. Today's reality: roughly half a million. The conditions for breakthrough change have arrived. Machine vision that was cost-prohibitive five years ago is now accessible. Robotics precise enough for chip assembly can be adapted for cellular manipulation. Advanced microscopy techniques have matured beyond research labs into clinical application.

AURA represents the convergence of these technologies—not as experimental prototypes, but as proven systems reapplied to a new domain. We didn't wait for fertility-specific innovations to be invented. We brought the best tools from other industries and put them to work where they matter most.

From Concierge Medicine to Population Health

Human-guided automation means IVF can transform from expensive concierge medicine into population-scale healthcare. Not through incremental improvement, but through systems-level reinvention.

The implications extend beyond efficiency:

• More affordable IVF services for families facing infertility

• Expansion to serve recurrent miscarriage, genetic disease prevention, and LGBTQ+ family-building

• Geographic accessibility for the 40% of Americans living in fertility deserts

This is The In Vitro Possible—recognizing that the tools to transform fertility care already exist.

They just needed someone to see the connection.

As Stuart Kauffman reminds us: what is actual now enables what is next possible.

The conditions have arrived. The technologies are proven. The Adjacent Possible isn't a future vision—it's happening now in labs where AURA is already helping achieve pregnancies.

Sometimes the best innovations don't come from inventing everything from scratch. They come from borrowing the best tools that already exist—and recognizing when the moment is right to put them together.